Abstract
Background: PABA/NO is a diazeniumdiolate that acts as a direct nitrogen monoxide (NO) donor and is in development as an anticancer drug. Its mechanism of action and effect on cells is not yet fully understood. Methodology/Principal Findings: We used HPLC and mass spectrometry to identify a primary nitroaromatic glutathione metabolite of PABA/NO and used fluorescent assays to characterize drug effects on calcium and NO homeostasis, relating these to endothelial nitric oxide synthase (eNOS) activity. Unexpectedly, the glutathione conjugate was found to be a competitive inhibitor of sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) presumably at the same site as thapsigargin, increasing intracellular Ca2+ release and causing auto-regulation of eNOS through S-glutathionylation. Conclusions/Significance: The initial direct release of NO after PABA/NO was followed by an eNOS-mediated generation of NO as a consequence of drug-induced increase in Ca2+ flux and calmodulin (CaM) activation. PABA/NO has a unique dual mechanism of action with direct intracellular NO generation combined with metabolite driven regulation of eNOS activation. © 2010 Manevich et al.
Cite
CITATION STYLE
Manevich, Y., Townsend, D. M., Hutchens, S., & Tew, K. D. (2010). Diazeniumdiolate mediated nitrosative stress alters nitric oxide homeostasis through intracellular calcium and s-glutathionylation of nitric oxide synthetase. PLoS ONE, 5(11). https://doi.org/10.1371/journal.pone.0014151
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.